Clinico-Pathologic Subtypes of Breast Cancer Primary Tumors Are Related to Prognosis after Recurrence |
Sanchez, Cesar
(Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile)
Camus, Mauricio (Department of Surgery, School of Medicine, Pontificia Universidad Catolica de Chile) Medina, Lidia (Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile) Oddo, David (Department of Pathology, School of Medicine, Pontificia Universidad Catolica de Chile) Artigas, Rocio (Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile) Sepulveda, Alejandra Perez (Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile) Domainguez, Francisco (Department of Surgery, School of Medicine, Pontificia Universidad Catolica de Chile) Razmilic, Dravna (Department of Radiology School of Medicine, Pontificia Universidad Catolica de Chile) Navarro, Maria Elena (Department of Radiology School of Medicine, Pontificia Universidad Catolica de Chile) Galindo, Hector (Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile) Acevedo, Francisco (Department of Hematology-Oncology, School of Medicine, Pontificia Universidad Catolica de Chile) |
1 | Hammond MEH, Hayes DF, Dowsett M, et al (2010). American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol, 28, 2784-95. DOI |
2 | Harris LN, Ismaila N, McShane LM, et al (2016). Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol, 34, 1134-50 DOI |
3 | Jonat W, Arnold N (2011). Is the Ki-67 labelling index ready for clinical use?. Ann Oncol, 22, 500-2. DOI |
4 | Kennecke H, Yerushalmi R, Woods R, et al (2010). Metastatic behavior of breast cancer subtypes. J Clin Oncol, 28, 3271-7. DOI |
5 | Pathmanathan N, Balleine RL (2013). Ki67 and proliferation in breast cancer. J Clin Pathol, 66, 512-6. DOI |
6 | Petric M, Martinez S, Acevedo F, et al (2014). Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy. Asian Pac J Cancer Prev, 15, 10277-80. |
7 | Sestak I, Cuzick J, Dowsett M, et al (2015). Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk. J Clin Oncol, 33, 916-22. DOI |
8 | Shim HJ, Kim SH, Kang BJ, et al (2014). Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev, 15, 5539-44. DOI |
9 | Sparano JA, Gray RJ, Makower DF, et al (2015). Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med, 373, 2005-14 DOI |
10 | Turner N, Biganzoli L, Malorni L, et al (2013). Adjuvant chemotherapy: which patient? what regimen? Am Soc Clin Oncol Educ Book, 33, 3-8 DOI |
11 | Wolff AC, Hammond MEH, Hicks DG, et al (2013). Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol, 31, 3997-4013. DOI |
12 | Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4. DOI |
13 | Zelnak AB, O'Regan RM (2013). Genomic subtypes in choosing adjuvant therapy for breast cancer. Oncology, 27, 204-10. |
14 | Acevedo F, Camus M, Sanchez C (2015). Breast Cancer at Extreme Ages - a Comparative Analysis in Chile. Asian Pac J Cancer Prev, 16, 1455-61. DOI |
15 | Cardoso F, Costa A, Norton L, et al (2014). ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol, 25, 1871-88. DOI |
16 | Cuzick J, Dowsett M, Pineda S, et al (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J Clin Oncol, 29, 4273-8. DOI |
17 | Dowsett M, Sestak I, Lopez-Knowles E, et al (2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol, 31, 2783-90. DOI |
18 | Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology, 41, 151-2. DOI |
19 | Goldhirsch A, Winer EP, Coates AS, et al (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol, 24, 2206-23. DOI |
![]() |